神経調節市場：技術別、用途別-2025～2030年の世界予測

神経調節市場は、2023年に77億6,000万米ドルと評価され、2024年には86億1,000万米ドルに達すると予測され、CAGR 11.50％で成長し、2030年には166億2,000万米ドルに達すると予測されています。

医療セグメントにおける先駆的な領域である調査手法には、神経に直接作用して治療効果を得る技術や手法が含まれ、電気刺激や薬剤の標的送達によって神経活動を変化させる。その必要性は、神経疾患の増加、慢性疼痛症候群、高齢化社会から生じ、効果的な管理ソリューションの必要性が生じています。応用範囲には、慢性疼痛管理、てんかん、パーキンソン病、うつ病、標的筋疾患などが含まれます。最終用途シナリオは、脊髄刺激装置、迷走神経刺激装置、脳深部刺激装置などを活用する病院、クリニック、在宅ケア環境を特徴とすることが多いです。市場力学では、技術的進歩、患者の意識向上、医療支出の増加といった主要な影響要因が成長を後押ししていることが明らかになっています。低侵襲手術の増加は有利な可能性を提供し、新規市場参入のフロンティアとなります。さらに、医療の枠組みが改善しつつある新興国は、未開拓のビジネス機会をもたらしています。しかし、高額な機器コスト、複雑な規制環境、潜在的な副作用などの制約が、市場の急速な拡大を制限しています。また、既存企業が先行者利益を得て新規参入を阻害していることも課題となっています。革新的な点では、ウェアラブル神経調節装置とAIによる治療レジメンの個別化が、従来のプラクティスを破壊する態勢を整えた肥沃な研究手段を浮き彫りにしています。さらに、神経アプリケーションにおける遠隔モニタリングのためのIoTの統合は、患者との相互作用と転帰を再定義する可能性があります。市場はダイナミックでありながら保守的な性質を持っており、市場シェアを獲得するには製品開拓と戦略的パートナーシップにおける機敏さが不可欠です。企業は、このような機会を活用するために、規制順守に沿った強固な研究開発イニシアチブに投資することが奨励され、デジタル技術の進歩を統合するためにハイテク企業とのコラボレーションを重視します。全体として、神経調節市場はハードルに直面しているが、ビジネスの持続的成長のためには、革新的なソリューションと臨床的有効性の橋渡しをすることに大きな可能性があります。

市場力学：急速に進化する神経調節市場の主要市場洞察を公開

神経調節市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、新たなビジネス機会の獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の高齢化人口の増加と神経疾患の蔓延
  • 神経刺激システムと神経調節ソリューションの調査イニシアティブと臨床検査
  • 神経疾患や障害の治療法へのアクセスを拡大するための政府の取り組み
• 市場抑制要因
  • 神経調節と神経刺激装置システムの製品回収の発生
• 市場機会
  • 神経調節戦略の効率性と安全性を最適化する技術革新
  • 世界中で神経調節デバイスと治療法の承認が進行中
• 市場課題
  • 技術の侵襲性と技術的限界

ポーターのファイブフォース：神経調節市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：神経調節市場における外部からの影響の把握

外部マクロ環境要因は、神経調節市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：神経調節市場における競合情勢の把握

神経調節市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的な意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：神経調節市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、神経調節市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：神経調節市場における成功への道筋を描く

神経調節市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力を評価します。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で高齢化が進み、神経疾患が蔓延している
    • 神経刺激システムとソリューションに関する調査イニシアチブと臨床検査
    • 神経疾患や障害に対する治療法へのアクセス拡大に向けた政府の取り組み
  • 抑制要因
    • 神経調節と神経刺激装置またはシステムの製品リコールの発生件数
  • 機会
    • 神経調節戦略の効率と安全性を最適化するイノベーション
    • 世界中で神経調節デバイスと治療法の承認が進行中
  • 課題
    • 技術の侵襲性と技術的限界
• 市場セグメンテーション分析
  • 技術：運動障害や精神疾患に対する脳深部刺激療法の必要性が高まっている
  • 用途：世界中でパーキンソン病の発症率が上昇
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 神経調節市場：技術別

• イントロダクション
• 脳深部刺激療法
• 胃刺激
• 仙骨神経刺激
• 脊髄刺激
• 迷走神経刺激

第7章 神経調節市場：用途別

• イントロダクション
• 慢性疼痛
• ジストニア
• 本態性振戦
• 胃不全麻痺
• 強迫性障害
• パーキンソン病
• 難治性てんかん
• 治療抵抗性うつ病
• 尿失禁

第8章 南北アメリカの神経調節市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋の神経調節市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの神経調節市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
  • GrayMatters Healthが米国でFDA承認の新しい自己神経調節PTSD治療法を開始
  • Dr. Reddyがインドで片頭痛管理用ウェアラブルを発表
  • Galderma、リキッドライブイベントで神経調節の大胆な野望を発表
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• BioControl by Merck
• BioElectronics Corporation
• Boston Scientific Corporation
• Dr Reddys Laboratories Limited
• EndoStim, Inc.
• Galderma S.A.
• GrayMatters Health
• Impulse Dynamics
• Livanova
• Mainstay Medical
• Medtronic PLC
• MicroTransponde
• NeuroMetrix
• Neuronetics, Inc.
• NeuroPace, Inc.
• NeuroSigma, Inc.
• Nevro Corp.
• Saluda Medical
• SceneRay Corporation, Limited
• Soterix Medical
• Synapse Biomedical

LIST OF FIGURES

• FIGURE 1. NEUROMODULATION MARKET RESEARCH PROCESS
• FIGURE 2. NEUROMODULATION MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL NEUROMODULATION MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL NEUROMODULATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL NEUROMODULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL NEUROMODULATION MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL NEUROMODULATION MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS NEUROMODULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS NEUROMODULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES NEUROMODULATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES NEUROMODULATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. NEUROMODULATION MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. NEUROMODULATION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. NEUROMODULATION MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL NEUROMODULATION MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL NEUROMODULATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL NEUROMODULATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. NEUROMODULATION MARKET DYNAMICS
• TABLE 7. GLOBAL NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL NEUROMODULATION MARKET SIZE, BY GASTRIC STIMULATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL NEUROMODULATION MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL NEUROMODULATION MARKET SIZE, BY DYSTONIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL NEUROMODULATION MARKET SIZE, BY ESSENTIAL TREMOR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL NEUROMODULATION MARKET SIZE, BY GASTROPARESIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL NEUROMODULATION MARKET SIZE, BY OBSESSIVE COMPULSIVE DISORDER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL NEUROMODULATION MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL NEUROMODULATION MARKET SIZE, BY REFRACTORY EPILEPSY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL NEUROMODULATION MARKET SIZE, BY TREATMENT RESISTANT DEPRESSION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL NEUROMODULATION MARKET SIZE, BY URINARY FECAL INCONTINENCE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS NEUROMODULATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 30. CANADA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 31. CANADA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 34. UNITED STATES NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES NEUROMODULATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 37. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 38. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 40. AUSTRALIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 41. AUSTRALIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 42. CHINA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 43. CHINA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 44. INDIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 45. INDIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 46. INDONESIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 47. INDONESIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 48. JAPAN NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 49. JAPAN NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 50. MALAYSIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 51. MALAYSIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 52. PHILIPPINES NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 53. PHILIPPINES NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 54. SINGAPORE NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 55. SINGAPORE NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 56. SOUTH KOREA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 57. SOUTH KOREA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 58. TAIWAN NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 59. TAIWAN NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 60. THAILAND NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 61. THAILAND NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 62. VIETNAM NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 63. VIETNAM NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 64. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 65. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 66. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 67. DENMARK NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 68. DENMARK NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 69. EGYPT NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 70. EGYPT NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 71. FINLAND NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 72. FINLAND NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 73. FRANCE NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 74. FRANCE NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 75. GERMANY NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 76. GERMANY NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 77. ISRAEL NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 78. ISRAEL NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 79. ITALY NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 80. ITALY NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 81. NETHERLANDS NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 82. NETHERLANDS NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 83. NIGERIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 84. NIGERIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 85. NORWAY NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 86. NORWAY NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 87. POLAND NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 88. POLAND NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 89. QATAR NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 90. QATAR NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 91. RUSSIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 92. RUSSIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 93. SAUDI ARABIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 94. SAUDI ARABIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 95. SOUTH AFRICA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 96. SOUTH AFRICA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 97. SPAIN NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 98. SPAIN NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 99. SWEDEN NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 100. SWEDEN NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 101. SWITZERLAND NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 102. SWITZERLAND NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 103. TURKEY NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 104. TURKEY NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 105. UNITED ARAB EMIRATES NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 106. UNITED ARAB EMIRATES NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 107. UNITED KINGDOM NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 108. UNITED KINGDOM NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 109. NEUROMODULATION MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 110. NEUROMODULATION MARKET, FPNV POSITIONING MATRIX, 2023

The Neuromodulation Market was valued at USD 7.76 billion in 2023, expected to reach USD 8.61 billion in 2024, and is projected to grow at a CAGR of 11.50%, to USD 16.62 billion by 2030.

Neuromodulation, a pioneering domain in the medical field, encompasses technologies and methodologies that directly act upon nerves to achieve a therapeutic effect, thus altering nerve activity through targeted delivery of electrical stimulation or pharmaceutical agents. Its necessity arises from rising neurological disorders, chronic pain syndromes, and an aging population, creating an imperative for effective management solutions. The application spectrum includes chronic pain management, epilepsy, Parkinson's disease, depression, and targeted muscle disorders. End-use scenarios often feature hospitals, clinics, and in-home care settings that leverage spinal cord stimulators, vagus nerve stimulators, and deep brain stimulators. Market dynamics reveal key influencers such as technological advancements, increasing patient awareness, and heightened healthcare expenditure which boost growth. The escalation of minimally invasive surgeries offers lucrative potential and marks a frontier for new market entrants. Furthermore, emergent economies with improving healthcare frameworks present untapped opportunities. However, limitations such as high device costs, complex regulatory environments, and potential side effects restrict rapid market expansion. Challenges also stem from first-mover advantages held by established players, inhibiting newer entrants. Innovatively, wearable neuromodulators and AI-driven personalization of treatment regimens highlight fertile research avenues poised to disrupt traditional practices. Additionally, the integration of IoT for remote monitoring in neural applications could redefine patient interactions and outcomes. The market holds a dynamic yet conservative nature, where nimbleness in product development and strategic partnerships is critical to captivate market share. Businesses are encouraged to invest in robust R&D initiatives that align with regulatory compliances to harness these opportunities, emphasizing collaborations with tech firms to integrate digital advancements. Overall, while the neuromodulation market faces hurdles, its vast potential lies in bridging innovative solutions with clinical efficacy for sustained business growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Neuromodulation Market

The Neuromodulation Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rise in the aging population across the world and prevalence of neurological disorders
  • Research initiatives and clinical trials for neurostimulation systems and neuromodulation solutions
  • Government initiatives to expand access to therapies for neurological diseases and disorders
• Market Restraints
  • Incidences of product recall of neuromodulation and neurostimulation devices or systems
• Market Opportunities
  • Innovations to optimize the efficiency and safety of neuromodulation strategies
  • Ongoing approvals for neuromodulation devices and treatments across the world
• Market Challenges
  • Invasiveness and technical limitations of the technology

Porter's Five Forces: A Strategic Tool for Navigating the Neuromodulation Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Neuromodulation Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Neuromodulation Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Neuromodulation Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Neuromodulation Market

A detailed market share analysis in the Neuromodulation Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Neuromodulation Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Neuromodulation Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Neuromodulation Market

A strategic analysis of the Neuromodulation Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Neuromodulation Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, BioControl by Merck, BioElectronics Corporation, Boston Scientific Corporation, Dr Reddys Laboratories Limited, EndoStim, Inc., Galderma S.A., GrayMatters Health, Impulse Dynamics, Livanova, Mainstay Medical, Medtronic PLC, MicroTransponde, NeuroMetrix, Neuronetics, Inc., NeuroPace, Inc., NeuroSigma, Inc., Nevro Corp., Saluda Medical, SceneRay Corporation, Limited, Soterix Medical, and Synapse Biomedical.

Market Segmentation & Coverage

This research report categorizes the Neuromodulation Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Technology, market is studied across Deep Brain Stimulation, Gastric Stimulation, Sacral Nerve Stimulation, Spinal Cord Stimulation, and Vagus Nerve Stimulation.
• Based on Application, market is studied across Chronic Pain, Dystonia, Essential Tremor, Gastroparesis, Obsessive Compulsive Disorder, Parkinson's Disease, Refractory Epilepsy, Treatment Resistant Depression, and Urinary Fecal Incontinence.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rise in the aging population across the world and prevalence of neurological disorders
    • 5.1.1.2. Research initiatives and clinical trials for neurostimulation systems and neuromodulation solutions
    • 5.1.1.3. Government initiatives to expand access to therapies for neurological diseases and disorders
  • 5.1.2. Restraints
    • 5.1.2.1. Incidences of product recall of neuromodulation and neurostimulation devices or systems
  • 5.1.3. Opportunities
    • 5.1.3.1. Innovations to optimize the efficiency and safety of neuromodulation strategies
    • 5.1.3.2. Ongoing approvals for neuromodulation devices and treatments across the world
  • 5.1.4. Challenges
    • 5.1.4.1. Invasiveness and technical limitations of the technology
• 5.2. Market Segmentation Analysis
  • 5.2.1. Technology: Increasing need for deep brain stimulation therapies for movement disorders and psychiatric issues
  • 5.2.2. Application: Rising incidences of Parkinson's disease across the world
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Neuromodulation Market, by Technology

• 6.1. Introduction
• 6.2. Deep Brain Stimulation
• 6.3. Gastric Stimulation
• 6.4. Sacral Nerve Stimulation
• 6.5. Spinal Cord Stimulation
• 6.6. Vagus Nerve Stimulation

7. Neuromodulation Market, by Application

• 7.1. Introduction
• 7.2. Chronic Pain
• 7.3. Dystonia
• 7.4. Essential Tremor
• 7.5. Gastroparesis
• 7.6. Obsessive Compulsive Disorder
• 7.7. Parkinson's Disease
• 7.8. Refractory Epilepsy
• 7.9. Treatment Resistant Depression
• 7.10. Urinary Fecal Incontinence

8. Americas Neuromodulation Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Neuromodulation Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Neuromodulation Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
  • 11.3.1. GrayMatters Health Launches New FDA-Cleared Self-Neuromodulation PTSD Therapy in the United States
  • 11.3.2. Dr. Reddy's Unveils Wearable for Migraine Management in India
  • 11.3.3. Galderma Unveils Bold Ambition in Neuromodulation at Liquid Live Event
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. BioControl by Merck
• 3. BioElectronics Corporation
• 4. Boston Scientific Corporation
• 5. Dr Reddys Laboratories Limited
• 6. EndoStim, Inc.
• 7. Galderma S.A.
• 8. GrayMatters Health
• 9. Impulse Dynamics
• 10. Livanova
• 11. Mainstay Medical
• 12. Medtronic PLC
• 13. MicroTransponde
• 14. NeuroMetrix
• 15. Neuronetics, Inc.
• 16. NeuroPace, Inc.
• 17. NeuroSigma, Inc.
• 18. Nevro Corp.
• 19. Saluda Medical
• 20. SceneRay Corporation, Limited
• 21. Soterix Medical
• 22. Synapse Biomedical